Clostridium (e.g., Clostridium Tetani, Clostridium Difficile, Clostridium Perfringens, Clostridium Botulinum, Clostridium Chauvoei, Etc.) Patents (Class 424/247.1)
-
Patent number: 8784841Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.Type: GrantFiled: April 27, 2009Date of Patent: July 22, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
-
Publication number: 20140193416Abstract: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[a-L-Rhap-(1?3]-a-D-Glcp-(1?2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier protein or for immobilization on a surface. Further aspects of the invention relate to advantageous methods for synthesizing said synthetic oligosaccharide and oligosaccharide-protein conjugate as well as to uses thereof, in particular as vaccines and diagnostic tools.Type: ApplicationFiled: July 30, 2012Publication date: July 10, 2014Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
-
Patent number: 8747841Abstract: The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of damage of the peripheral or central nervous system.Type: GrantFiled: March 31, 2010Date of Patent: June 10, 2014Inventors: Gudrun Ahnert-Hilger, Gisela Groβe, Fred Hofmann, Ingo Just, Markus Höltje, Stefanie Hülsenbeck
-
Patent number: 8747865Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: GrantFiled: January 15, 2013Date of Patent: June 10, 2014Assignee: Allergan, Inc.Inventor: Alan H. Ackerman
-
Patent number: 8728491Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: GrantFiled: May 7, 2008Date of Patent: May 20, 2014Assignee: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Patent number: 8722060Abstract: The invention is a method for reducing the symptoms of vertigo. The method is performed by delivering a therapeutically effective amount of presynaptic neurotoxin, such as Botulinum Toxin A, in a pharmaceutically safe form to suitable locations around the head and neck.Type: GrantFiled: May 23, 2012Date of Patent: May 13, 2014Inventor: William J. Binder
-
Publication number: 20140127263Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: OmniGen Research, L.L.C.Inventors: Neil E. Forsberg, Steven B. Puntenney
-
Patent number: 8715620Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: GrantFiled: December 22, 2010Date of Patent: May 6, 2014Inventor: Ira Sanders
-
Publication number: 20140112951Abstract: Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.Type: ApplicationFiled: August 7, 2013Publication date: April 24, 2014Applicant: UAB RESEARCH FOUNDATIONInventors: De-Chu C. Tang, Zhongkai Shi, Kent Rigby van Kampen
-
Patent number: 8697066Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.Type: GrantFiled: January 31, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
-
Patent number: 8697090Abstract: A method of controlling dysregulation of the dorsal cutaneous nerve of the clitoris and, in particular, a method for treating PGAD is provided. In one aspect, the method comprises administering a neurotoxin, such as a botulinum toxin, to the clitoral area of the human in need of treatment.Type: GrantFiled: May 4, 2012Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventor: Marlon P. Rimando
-
Patent number: 8685414Abstract: Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles.Type: GrantFiled: November 7, 2011Date of Patent: April 1, 2014Inventor: Christopher A. Dadas
-
Patent number: 8658391Abstract: The present invention provides methods for assessing the activity of topically administered chemodenervating agents. In some embodiments, methods for assessing the activity of topically administered chemodenervating agents involve determining the extent of inhibition of acetylcholine release near the site of administration. In some embodiments, methods for assessing activity of topically administered chemodenervating agents involve observing a reflex motion of a limb of a subject.Type: GrantFiled: April 27, 2007Date of Patent: February 25, 2014Assignee: Anterios, Inc.Inventor: Jonathan Edelson
-
Patent number: 8652489Abstract: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.Type: GrantFiled: January 10, 2013Date of Patent: February 18, 2014Assignee: Merz Pharma GmbH & Co., KGaAInventor: Harold Victor Taylor
-
Publication number: 20140037716Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.Type: ApplicationFiled: March 19, 2012Publication date: February 6, 2014Inventor: Alexandre Eduardo Nowill
-
Patent number: 8642047Abstract: A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol.Type: GrantFiled: February 9, 2012Date of Patent: February 4, 2014Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8632786Abstract: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.Type: GrantFiled: November 14, 2011Date of Patent: January 21, 2014Assignee: DT Scimed, LLCInventor: L. Andrew Koman
-
Patent number: 8632785Abstract: A botulinum toxin pharmaceutical formulation comprising a botulinum toxin and a low molecular weight recombinant or native gelatin fragment suitable for administration to a human patient, and methods for treating patients with various diseases and afflictions using the formulation.Type: GrantFiled: November 29, 2005Date of Patent: January 21, 2014Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8629100Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.Type: GrantFiled: July 24, 2013Date of Patent: January 14, 2014Assignee: The Medicines CompanyInventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
-
Publication number: 20140004150Abstract: The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.Type: ApplicationFiled: April 8, 2011Publication date: January 2, 2014Applicants: CHINA 302 MILITARY HOSPITAL OF PLAInventors: Jiabo Wang, Xiaohe Xiao, Zhewei Wang, Cheng Jin, Qi Li
-
Patent number: 8617571Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.Type: GrantFiled: April 3, 2008Date of Patent: December 31, 2013Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8617572Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.Type: GrantFiled: March 22, 2011Date of Patent: December 31, 2013Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8617573Abstract: It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or Clostridium botulinum and kits for use thereof.Type: GrantFiled: October 26, 2011Date of Patent: December 31, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Edwin Raymond Chapman, Min Dong
-
Publication number: 20130344104Abstract: The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium difficile glycopolymer PS-II and a protein carrier. More specifically, the oligosaccharide is the hexasaccharide having the following formula (I) wherein R is a linker or spacer group. In a specific embodiment of the invention, R is (CH2)nNH2, with n being an integer from 2 to 50. The present invention also provides the use of said oligosaccharide and said oligosaccharide-protein conjugate for the treatment or prevention of a disease caused by the pathogen Clostridium difficile. In still further aspects, the present invention also provides a favourable method for preparing said oligosaccharide and said oligosaccharide-protein conjugate.Type: ApplicationFiled: March 7, 2012Publication date: December 26, 2013Inventors: Peter H. Seeberger, Matthias Oberli, Marie-Lyn Hecht
-
Patent number: 8609113Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.Type: GrantFiled: February 1, 2013Date of Patent: December 17, 2013Assignee: Allergan, Inc.Inventors: Andrew M. Blumenfeld, Catherine C. Turkel, Mitchell F. Brin
-
Patent number: 8609112Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.Type: GrantFiled: February 1, 2013Date of Patent: December 17, 2013Assignee: Allergan, Inc.Inventors: Andrew M. Blumenfeld, Catherine C. Turkel, Mitchell F. Brin
-
Patent number: 8609111Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: GrantFiled: June 7, 2012Date of Patent: December 17, 2013Assignees: University of Massachusetts, Medarex, L.L.C.Inventors: Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
-
Patent number: 8597663Abstract: The application relates to Clostridium difficile cell surface polysaccharides, compositions comprising Clostridium difficile cell surface polysaccharides, and includes kits, methods and uses thereof.Type: GrantFiled: September 11, 2008Date of Patent: December 3, 2013Assignee: University of GuelphInventors: Mario Artur Monteiro, Nagalingham Ganeshapilla, Mononmanydevi Ganeshapilla
-
Publication number: 20130315959Abstract: The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The saccharides may be used in vaccines, particularly as conjugates with carrier proteins.Type: ApplicationFiled: December 23, 2011Publication date: November 28, 2013Applicant: NOVARTIS AGInventors: Paolo Costantino, Roberto Adamo, Maria Rosaria Romano, Elisa Danieli, Francesco Berti, Emilia Cappelliti, Luigi Lay
-
Patent number: 8586329Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain of the neurotoxin polypeptide as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: GrantFiled: July 1, 2010Date of Patent: November 19, 2013Assignee: Merz Pharma GmbH & Co. KGaAInventors: Fred Hofmann, Jurgen Frevert
-
Patent number: 8568740Abstract: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum-containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.Type: GrantFiled: November 16, 2006Date of Patent: October 29, 2013Assignee: Revance Therapeutics, Inc.Inventor: Jacob M. Waugh
-
Patent number: 8557255Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.Type: GrantFiled: June 29, 2007Date of Patent: October 15, 2013Assignee: Merz Pharma GmbH & Co. KGaAInventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler
-
Patent number: 8557256Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: GrantFiled: June 12, 2003Date of Patent: October 15, 2013Assignee: Allergan, Inc.Inventors: Kei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Publication number: 20130266583Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: October 5, 2011Publication date: October 10, 2013Applicants: MICROPHARM LIMITED, HEALTH PROTECTION AGENCYInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20130259948Abstract: The present invention relates to a novel effective dry powder vaccine formulation that increases the immune response in the host. The formulation comprises of an antigen entrapped into a polymer particle, coated with alum, finally spray dried into a dry powder. This formulation is used to elicit long lasting higher antibody titers than alum adsorbed antigen or admixture of polymer entrapped antigen and alum.Type: ApplicationFiled: September 20, 2011Publication date: October 3, 2013Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Amulya Kumar Panda, Anish Chakkunkal, Dinesh Giri Goswami
-
Patent number: 8530410Abstract: Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction.Type: GrantFiled: April 16, 2010Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 8518417Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.Type: GrantFiled: July 11, 2007Date of Patent: August 27, 2013Assignee: Allergan, Inc.Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
-
Patent number: 8518873Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.Type: GrantFiled: September 11, 2008Date of Patent: August 27, 2013Assignee: The Medicines CompanyInventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
-
Patent number: 8501190Abstract: There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or variant thereof, a nucleic acid encoding the C. perfringens antigenic polypeptide or variant thereof, or a recombinant cell producing the C. perfringens antigenic polypeptide or variant thereof.Type: GrantFiled: May 30, 2008Date of Patent: August 6, 2013Assignee: The University of GuelphInventors: John Prescott, Raveendra Kulkarni, Valeria Parreira, Shayan Sharif
-
Patent number: 8501196Abstract: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.Type: GrantFiled: May 9, 2012Date of Patent: August 6, 2013Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Patent number: 8486422Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.Type: GrantFiled: June 27, 2008Date of Patent: July 16, 2013Inventors: Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
-
Patent number: 8470337Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.Type: GrantFiled: March 13, 2008Date of Patent: June 25, 2013Assignee: Allergan, Inc.Inventors: Aubrey N. Manack, Mitchell F. Brin
-
Patent number: 8465752Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.Type: GrantFiled: April 22, 2010Date of Patent: June 18, 2013Assignee: Mercator Medsystems, Inc.Inventor: Kirk Patrick Seward
-
Publication number: 20130149339Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.Type: ApplicationFiled: June 3, 2011Publication date: June 13, 2013Applicant: The University of TokyoInventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
-
Patent number: 8454975Abstract: A method for treating skin by administration of a neurotoxin such as a botulinum toxin by means of a dry needle. The method can be used to accomplish what has generally been described as skin rejuvenation and also to treat skin disorders such as skin lines, crepiness, excess skin, wrinkles, platysmal bands, uneven skin tone and color, and hyperhidrosis.Type: GrantFiled: January 7, 2011Date of Patent: June 4, 2013Inventor: Elizabeth VanderVeer
-
Patent number: 8454976Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: July 17, 2008Date of Patent: June 4, 2013Assignees: Syntaxin Limited, Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8449893Abstract: A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes of such a composition are also claimed.Type: GrantFiled: December 15, 2009Date of Patent: May 28, 2013Assignee: Bayer New Zealand Limited (17012)Inventor: Wayne Frederick Leech
-
Publication number: 20130129783Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: ApplicationFiled: January 15, 2013Publication date: May 23, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Patent number: 8440203Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: GrantFiled: November 6, 2009Date of Patent: May 14, 2013Assignee: Intervet Inc.Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Patent number: 8414902Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.Type: GrantFiled: June 10, 2010Date of Patent: April 9, 2013Inventor: Eric Finzi